EFS MASTER CLINICAL TRIAL AGREEMENTMaster Clinical Trial Agreement • October 19th, 2021
This MASTER CLINICAL TRIAL AGREEMENT (“Agreement”) is made effective as of the [NUMBER] day of [MONTH], [YEAR] (the “Effective Date”), and is by and between [SPONSOR NAME], a [ ] corporation, with offices at [ADDRESS] (“SPONSOR”) and [INSTITUTION NAME], a [ ] corporation with offices at [ADDRESS] (“Institution”).
ContractMaster Clinical Trial Agreement • May 19th, 2016 • Indiana
NOTE: This document is only a template. It is subject to change depending upon the specific needs of a study. In order for it to be considered ready for execution, it must be reviewed by the IU Clinical Trials Office and agreed upon by the applicable parties. If you have any questions, please contact the IU Clinical Trials Office at 317-278-2546 and/or cto@iu.edu
Please delete this page upon discussion or finalisation of document]Master Clinical Trial Agreement • January 3rd, 2024
The clauses in this Master Clinical Trial Agreement (MCTA) have been reviewed and agreed by legal representatives from Singapore Association of Pharmaceutical Industries (SAPI), Singapore Health Services (SingHealth), National Healthcare Group (NHG) and National University Health System (NUHS) with the aim to expedite agreement review process between Sponsor and Singapore’s Public Healthcare Institutions.
MASTER CLINICAL TRIAL AGREEMENT AMENDMENT 2 FOR RENEWALMaster Clinical Trial Agreement • August 25th, 2020
This Master Clinical Trial Agreement Amendment No. 2 (hereinafter the “AMENDMENT No. 2”) effective as of 13 August 2020, hereinafter the “Amendment Effective Date”, and is by and between UCB BIOSCIENCES, INC. with an address at 8010 Arco Corporate Drive, Raleigh, NC 27617 ("SPONSOR”) and the following member institutions of The University of Texas System, (“SYSTEM”), having a place of business at 210 West 7th Street, Austin , TX 78701, as governed by its Board of Regents (“Board”): THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON, THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO, THE UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON, THE UNIVERSITY OF TEXAS AT AUSTIN, THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER, and THE UNIVERSITY OF TEXAS RIO GRANDE VALLEY
ContractMaster Clinical Trial Agreement • January 23rd, 2017
AMENDMENT NO. 1to the Master Clinical Trial Agreement dated as of 28 June 2016 (“Agreement”) DODATEK č. 1K Rámcové Smlouvě o klinickém hodnocení uzavřenou dne 28.06.2016 (“Smlouva”) by and between Boehringer Ingelheim RCV GmbH & Co KGDr. Boehringer-Gasse 5-11,1121 Vienna, AustriaVAT-ID-No.: ATU 64226215(hereinafter referred to as "Sponsor") Uzavřena mezi Boehringer Ingelheim RCV GmbH & Co KGDr. Boehringer-Gasse 5-11,1121 Vienna, AustriaDIČ: ATU 64226215(dale jen „Zadavatel”) and Fakultní nemocnice Olomouc,I.P. Pavlova 6, 779 00 Olomouc Responsible unit: doc. MUDr. Roman Havlík, Ph.D., ředitel VAT-ID-No. resp. Taxpayer Ident. No.: 00098892/ CZ00098892(hereinafter referred to as "Institution") a Fakultní nemocnice Olomouc,I.P. Pavlova 6, 779 00 Olomouc, Czech RepublicOdpovědný útvar: doc. MUDr. Roman Havlík, Ph.D., ředitel DIČ/IČ:00098892/ CZ00098892(dále jen „Zdravotnické zařízení“) WHEREAS, Sponsor and Institution have entered into the Agreement. WHEREAS, Sponsor and Institution desire
MASTER CLINICAL TRIAL AGREEMENTMaster Clinical Trial Agreement • April 16th, 2020 • Immatics B.V. • Texas
This Master Clinical Trial Agreement (this “Agreement”) is entered into as of December 1, 2016 (the “Effective Date”), by and between Immatics US, Inc. (“Sponsor”), having a principal place of business at 2130 Holcombe, Suite 11.3000, Houston, Texas 77030 and The University of Texas MD Anderson Cancer Center (“Study Site”), an agency of the State of Texas and a member institution of The University of Texas System (“System”), located at 1515 Holcombe Blvd., Houston, Texas 77030. Sponsor and the Study Site are sometimes referred to herein individually as a “Party” and collectively as “Parties.”
Dear NeuroNEXT PI, Site PI, and Site Coordinator -Master Clinical Trial Agreement • September 14th, 2018
NN1XX – STUDY NAME. Below you will find some additional information about account set up, per subject fees, additional budget items and site payments.
Exhibit 10.11 MASTER CLINICAL TRIAL AGREEMENT THIS MASTER CLINICAL TRIAL AGREEMENT (the "Agreement") is effective January 9, 2006 (the "Effective Date") between Cleveland Clinic Florida, a Florida not-for-profit corporation ("CCF"), and Ivivi...Master Clinical Trial Agreement • June 19th, 2006 • Ivivi Technologies, Inc. • Electromedical & electrotherapeutic apparatus • New Jersey
VIRTUAL LEGAL ROUNDTABLE – 2019 EFS MASTER CLINICAL TRIAL AGREEMENTMaster Clinical Trial Agreement • October 1st, 2021
• Goal - Develop an EFS-specific Master Clinical Trial Agreement (MCTA) to facilitate efficiencies in the EFS contracting process which provides:
THIRD AMENDMENT TO THE MASTER CLINICAL TRIAL AGREEMENTMaster Clinical Trial Agreement • September 17th, 2014
This Third Amendment (“Third Amendment”) effective as of September 16, 2014 hereby amends the Master Clinical Trial Agreement dated March 16, 2009, Amendment #1 thereto dated May 31, 2012, and Amendment #2 thereto dated March 16, 2014, between The University of Texas Health Science Center at San Antonio, The University of Texas Health Science Center at Houston, The University of Texas Southwestern Medical Center, The University of Texas Medical Branch at Galveston, The University of Texas Health Science Center at Tyler and The University of Texas at Austin, (individually and collectively referred to as an “Institution”) and Hoffmann-La Roche Inc. and Roche Laboratories Inc. (each referred to as “Roche”) (the “Master Agreement (as amended)”) (each a “Party” and collectively the “Parties”).
Active Master Clinical Trial Agreements 11/29/2017Master Clinical Trial Agreement • November 29th, 2017
Sponsor Amendments Effective Date Termination Date Abbott Vascular Inc. 1 and 2 3/17/2011, last amended 8/6/2013 None Abiomed, Inc. 1/30/2008 None Amgen, Inc. 8/18/2005 None Astellas Pharma Global Development, Inc. 10/2/2014 10/1/2019 AstraZeneca LP (Confidentiality Agreement) 1/22/2015 1/21/2020 Bayer Healthcare Pharmaceuticals, Inc 10/14/2014 10/13/2019 Beckman Coulter, Inc. 2/16/2011 2/15/2016 Biogen Idec, Inc 2/13/2014 2/12/2019 Boehringer Ingelheim Pharmaceuticals, Inc. (MCDA) 12/19/2016 12/18/2026 Boehringer Ingelheim Pharmaceuticals, Inc. (MCTA) 1/3/2017 1/2/2022 Celgene Corporation 1 5/2/2011 5/2/2021 Eli Lilly and Company: Lilly Research Laboratories 3/11/2005 None Genentech, Inc. 5/31/2017 5/30/2027 Gilead Sciences, Inc. 1 and 2 11/21/2007, last amended 8/12/2013 11/20/2019 Johnson & Johnson Vision Care, Inc. 1 10/10/2011 10/11/2019 Merck & Co., Inc. 5/15/2014 None Novartis Pharmaceuticals Corporation 1, 2, 3, 4. and 5 9/7/2005, last amended 9/1/2015 8
Master Clinical Trial AgreementsMaster Clinical Trial Agreement • July 10th, 2006
A master clinical trial agreement (MCTA) is a contract between a sponsor and a site that applies to multiple studies. It may or may not apply to all studies that site conducts for that sponsor. By negotiating a single agreement, the parties can avoid duplicating the effort of negotiating a separate clinical trial agreement (CTA) for every study. MCTAs avoid awkward answers to the site complaint: “You agreed to this term last time.”
ContractMaster Clinical Trial Agreement • August 29th, 2023
AMENDMENT NO. 1to theMaster Clinical Trial Agreement dated as of 23.05.2016 (“Agreement”) DODATEK Č.1 k Rámcové smlouvě o klinickém hodnocení podepsané dne 23.5.2016(dale jen “Smlouva) by and between Boehringer Ingelheim RCV GmbH & Co KGDr. Boehringer-Gasse 5-11,1121 Vienna AustriaVAT-ID-No.: ATU 64226215(hereinafter referred to as "Sponsor") mezi Boehringer Ingelheim RCV GmbH & Co KGDr. Boehringer-Gasse 5-11,1121 Vídeň, RakouskoDIČ: ATU 64226215(dále Jen „Zadavatel“) and Institute of Rheumatology, Na Slupi 4, 128 50, Prague 2 Responsible unit: Department of Clinical TrialsVAT-ID-No. resp. Taxpayer Ident. No.:CZ000237238(hereinafter referred to as "Institution") a Revmatologický ústav, Na Slupi 4, 128 50, Praha 2 Odpovědný útvar:Oddělení Klinických Hodnocení DIČ/IČ: CZ00023728(Dále Jen „Zdravotnické Zařízení“) WHEREAS, Sponsor and Institution have entered into the Agreement. WHEREAS, Sponsor and Institution desire to continue the successful relationship by altering the Agreement in ce
EFS MASTER CLINICAL TRIAL AGREEMENTMaster Clinical Trial Agreement • August 16th, 2021
This MASTER CLINICAL TRIAL AGREEMENT (“Agreement”) is made effective as of the [NUMBER] day of [MONTH], [YEAR] (the “Effective Date”), and is by and between [SPONSOR NAME], a [ ] corporation, with offices at [ADDRESS] (“SPONSOR”) and [INSTITUTION NAME], a [ ] corporation with offices at [ADDRESS] (“Institution”).
MASTER CLINICAL TRIAL AGREEMENT(“Agreement”) entered into as of 20 October 2016 (the "Effective Date") by and between Boehringer Ingelheim RCV GmbH & Co KGDr. Boehringer-Gasse 5-11, 1121 Vienna, AustriaVAT-ID-No.: ATU 64226215("Sponsor”) andGeneral...Master Clinical Trial Agreement • November 7th, 2020
RECITALS WHEREAS, Sponsor, a research-driven pharmaceutical company, is sponsoring and conducting a clinical trials of various compounds (“Investigational Product”) according to a specific Clinical Trial Protocol for each clinical trial (“Protocol”); and WHEREAS, Institution may, subject to written agreement, participate as an investigative site in one or more clinical trials (hereinafter referred to as “Trial” and collectively the “Trials”); and WHEREAS, Sponsor may engage a Contract Research Organisation (“CRO”), to act as an independent contractor, but not as a party to this Agreement, to carry out on behalf of Sponsor certain of Sponsor’s responsibilities with respect to the Trial, which may include, but are not limited to, contract negotiation and management, site payment, site monitoring, and/or other Trial related activities; and WHEREAS, Sponsor seeks to engage the services of Institution to carry out a Trial in accordance with the Protocol; and WHEREAS, Institution operates a
Master Clinical Trial AgreementMaster Clinical Trial Agreement • October 21st, 2019 • Kazia Therapeutics LTD • Pharmaceutical preparations • New York
A Kazia is a global biotechnology company engaged in the research and development of therapeutic products or devices for patients with cancer.
ContractMaster Clinical Trial Agreement • September 5th, 2016
RECITALSWHEREAS, Sponsor and Institution entered into a Master Clinical Trial Agreement (“Agreement”) effective on 18th November, 2013; andWHEREAS, pursuant to Section 2 of the Agreement, Sponsor, Institution and Investigator wish to enter into this ICTA for the purpose of setting forth the Protocol Number, Protocol Title and specific terms and conditions for the conduct of an individual clinical trial; andNOW, THEREFORE, pursuant to and subject to the terms and conditions of the Agreement and in consideration of the promises and mutual covenants contained herein, the Parties agree to the following: ÚVODNÍ USTANOVENÍVZHLEDEM K TOMU, ŽE Zadavatel a Zdravotnické zařízení uzavřeli s účinností ke dni18. 11. 2013 Rámcovou smlouvu o klinickém hodnocení (dále jen „Smlouva“); aVZHLEDEM K TOMU, ŽE podleustanovení článku 2 Smlouvy si Zadavatel, Zdravotnické zařízení a Zkoušející přejí uzavřít tuto SKKH, kterou stanoví číslo protokolu, název protokolu a konkrétní podmínky pro provádění konkrétníh
MASTER CLINICAL TRIAL AGREEMENT Sponsor-Initiated Studies OnlyMaster Clinical Trial Agreement • July 15th, 2009 • Texas
This Master Clinical Trial Agreement ("Agreement") is entered into by and between NeoPharm, Inc. with principal offices located at 150 Field Drive, Suite 195, Lake Forest, IL 60045 ("NeoPharm") and each of The University of Texas Health Science Center at San Antonio, The University of Texas Health Science Center at Houston, The University of Texas MD Anderson Cancer Center, The University of Texas Health Center at Tyler, The University of Texas Medical Branch at Galveston, and The University of Texas Southwestern Medical Center at Dallas (each an "Institution", and collectively "Institutions"), each with an office and place of business as set forth on Exhibit B hereto, and each a component institution of The University of Texas System located at 201 West 7th Street, Austin TX 78701 ("System"). Each Institution and NeoPharm may be referred to individually as a "party", and jointly as "parties". This agreement is effective as of the date of full execution ("Effective Date").
FOURTH AMENDMENT TO THE MASTER CLINICAL TRIAL AGREEMENTMaster Clinical Trial Agreement • December 1st, 2014
This Fourth Amendment (“Fourth Amendment”) effective as of November 16, 2014 hereby amends the Master Clinical Trial Agreement dated March 16, 2009, Amendment #1 thereto dated May 31, 2012, and Amendment #2 thereto dated March 16, 2014, and Amendment #3 thereto dated September 16, 2014, between The University of Texas Health Science Center at San Antonio, The University of Texas Health Science Center at Houston, The University of Texas Southwestern Medical Center, The University of Texas Medical Branch at Galveston, The University of Texas Health Science Center at Tyler and The University of Texas at Austin, (individually and collectively referred to as an “Institution”) and Hoffmann-La Roche Inc. and Roche Laboratories Inc. (each referred to as “Roche”) (the “Master Agreement (as amended)”) (each a “Party” and collectively the “Parties”).
INVESTIGATOR-SPONSORED MASTER CLINICAL TRIAL AGREEMENTMaster Clinical Trial Agreement • April 3rd, 2018 • Y-mAbs Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS INVESTIGATOR-SPONSORED TRIAL AGREEMENT (together with Appendix A, the “Agreement”) is made as of the date last signed below (the “Effective Date”) by and among Y-mAbs Therapeutics, Inc, a corporation with offices at 750 Third Avenue, 9th floor, New York, NY 10017 (“Company”), on the one hand; and MEMORIAL SLOAN KETTERING CANCER CENTER, a New York not-for-profit corporation with principal offices at 1275 York Avenue, New York, New York 10065, on behalf of Memorial Hospital for Cancer and Allied Diseases, its Regional Network sites, MSK Alliance Clinical Trial Sites, and its Cancer Health Equity Research Program Sites (“MSK”), and on behalf of itself and its employee specified in the applicable Study Addendum (“Investigator-Sponsor”), on the other hand. The parties agree that INVESTIGATOR-SPONSOR is not a party to this Agreement.
